Study of FORE8394 for cancers with BRAF changes
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 8 years or older and weigh at least 55 pounds (25 kg).
- Your tumor has a specific change in the BRAF gene (like a fusion or mutation).
- You have tried standard treatments, or they aren't right for you.
- You must be willing to provide a small piece of your tumor for testing.
- You need to be able to swallow pills (the drug is taken by mouth).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HSK42360, for people with advanced solid tumors that have a specific gene change called BRAF V600. It may be an option if other treatments have stopped working.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This study tests a new targeted drug called plixorafenib, either alone or combined with another drug (retifanlimab), for people with a BRAF-mutated brain tumor. The goal is to see if the drug can reach the brain and control the tumor, while checking for side effects.
This trial tests a drug called Belvarafenib for people with brain tumors that have a BRAF gene change (mutation). The drug targets this specific change to try to shrink or control the tumor. It is for patients whose brain tumor has come back or hasn't responded to other treatments.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
Hear when a new HGG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.